Trial · NCT01416636
Results by group76
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 76
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in 6-minute Walk Test Distance After 24 Weeks | High Dose | 45.43 | Standard Deviation 71.29 | m | |
| Change in 6-minute Walk Test Distance After 24 Weeks | Low Dose | 3.83 | Standard Deviation 56.21 | m | |
| Number of Participants With Clinical Worsening | High Dose | 7 | Participants | ||
| Number of Participants With Clinical Worsening | Low Dose | 12 | Participants | ||
| Effect on Maximal Borg Score During 6-minutes Walk Test | High Dose | -0.44 | Standard Deviation 2.21 | units on a scale | |
| Effect on Maximal Borg Score During 6-minutes Walk Test | Low Dose | -0.13 | Standard Deviation 2.43 | units on a scale | |
| Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class | High Dose | Improved | 27 | Participants | |
| Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class | Low Dose | Improved | 9 | Participants | |
| Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class | High Dose | No change | 22 | Participants | |
| Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class | Low Dose | No change | 36 | Participants | |
| Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class | High Dose | Worse | 2 | Participants | |
| Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class | Low Dose | Worse | 3 | Participants | |
| Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class | High Dose | Not done | 2 | Participants | |
| Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class | Low Dose | Not done | 4 | Participants | |
| Effect on Quality of Life by the MINNESOTA Questionnaire | High Dose | -6.36 | Standard Deviation 22.9 | units on a scale | |
| Effect on Quality of Life by the MINNESOTA Questionnaire | Low Dose | -4.63 | Standard Deviation 19.34 | units on a scale | |
| Effect on N-terminal Pro-BNP Levels | High Dose | 0.84 | Standard Deviation 63.32 | percentage change to baseline | |
| Effect on N-terminal Pro-BNP Levels | Low Dose | 41.68 | Standard Deviation 104.2 | percentage change to baseline | |
| Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance) | High Dose | -214.23 | Standard Deviation 324.28 | dyn.s.cm^-5 | |
| Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance) | Low Dose | 72.96 | Standard Deviation 284.95 | dyn.s.cm^-5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01416636/results